Overview

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Status:
Enrolling by invitation

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

NeuroActiva, Inc.

Collaborator:

Biomed Industries, Inc.

Treatments:

Neuroprotective Agents
Vaccines